Takaaki Terahara, PhD

Hisamitsu Pharmaceutical Co, Inc., Chiyoda-ku, Tokyo, Japan

JCP
Transdermal HP-3070 for Hostility in Schizophrenia
Original Research

June 6, 2022

Schizophrenia is sometimes accompanied by aggressive, hostile behavior, particularly during the acute phase. This post hoc analysis of a phase 3 study examines the efficacy of transdermal asenapine (HP-3070)...
Leslie Citrome, Marina Komaroff, Brittney Starling, et al
JCP
Original Research

December 15, 2020

Transdermal asenapine administration may address unmet needs in patients with schizophrenia, including improved adherence. This phase 3 study assessed efficacy and safety of HP-3070, an asenapine transdermal system (patch),...
Leslie Citrome, David P. Walling, Courtney M. Zeni, et al

Celebrating
85 Years

Read the Journal of Clinical Psychiatry

Subscribe to read
more articles

Subscribe